Montelukast API Market Highlights
The Montelukast API Market outlook report anticipates the industry to reach at 12.50% CAGR during the forecast period 2022-2030.
The asthma segment is expected to lead the market and register a substantial CAGR owing to the rising prevalence of asthma. Montelukast API is much in demand across the globe for the treatment of asthma. However, the allergic rhinitis segment is projected to exhibit the highest CAGR. The rising rate of allergic rhinitis cases is driving the growth of the segment.
North America accounted for the largest market share, and the regional market is projected to register a good CAGR during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate during the forecast period from 2022 to 2030.
The global montelukast API market has been segmented on the basis of applications, and region. On the basis of the applications, the market has been divided into asthma, allergic rhinitis, bronchospasm, urticarial and others. The asthma segment held the majority market share. Allergic rhinitis segment is expected to be the fastest-growing, followed by the asthma segment. Rising prevalence of allergic rhinitis is driving the growth of the segment.
North America accounted for the largest market share of 39.25% in 2017, and the regional market is projected to register a CAGR of 3.12% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.10% during the forecast period from 2018 to 2023.
The European market is estimated to exceed USD 396,258 thousand by 2023. Increasing incidence of asthma, COPD, and allergies are driving the growth of the Montelukast API market in the region. The UK is the major contributor to the growth of the regional market, followed by France.
Market Research Future (MRFR) recognizes Merck Sharp & Dohme Corp (US), Dr. Reddy’s Laboratories Ltd (India), Morepen Laboratories Ltd (India), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (Israel), Hikma Pharmaceuticals PLC (UK), Glenmark (India), Sandoz International GmbH (Germany), Vintage Pharmaceuticals Inc (US), Hetero (India) and Aurobindo Pharma (India) as the key players mentioned in the montelukast API market insights report.
Key Findings of the Study:
- The Montelukast API Market is anticipated to reach at 12.50% CAGR during the forecast period 2022-2030.
- North America accounted for the largest market share with the US being the major contributor to the growth of the market.
- The allergic rhinitis segment is projected to register the highest CAGR during the forecast period owing to the rising rate of allergic rhinitis cases.
- Key manufacturers are adopting geographic expansions, corporate acquisitions, and product launches as growth strategies.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)